Wound Care Business in Crisis
BioAventis has agreed to sell its wound business to LifeNet Health, which includes skin substitutes TheraSkin and TheraGenesis. The transaction includes a total cash consideration of $85 million.
Industry insights into this move
Bioventus bought Misonix, primarily for the BoneScapel product to be used in the spine. The deal also included TheraSkin, TheraGenesis, and SonicOne, a reasonably comprehensive wound portfolio.
BioAventis has agreed to sell its wound business to LifeNet Health, which includes skin substitutes TheraSkin and TheraGenesis. The transaction includes a total cash consideration of $85 million.
Why is everyone worried about the wound care market?
The problem with wound care is that it is a vastly different model than orthopedics, with a complex reimbursement structure for skin substitutes. CMS is proposing changes to the reimbursement of skin substitutes, dramatically impacting the wound care market. This change would reclassify all cellular and/or tissue-based products (CTPs) for skin wounds as “supplies incident to a physician service,” and package payment for these “supplies” into the practice expense associated with that service. This will kill the office-based skin substitute business for most orthopedic and podiatric practices.
Recent Posts
See AllThe " Same Rate for Same Service" concept argues that services should be paid equally, regardless of where they are provided. This...
For years, the emphasis on focal cartilage lesions has been primarily on restoring the cartilage cap. However, evolving knowledge...
David (niche bunion company Treace Medical Concepts ) takes on Goliath ( Stryker Corporation ) with a newly announced lawsuit , alleging...
Comments